Barinthus Biotherapeutics plc. (BRNS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BRNS currently has 40.8M outstanding shares. with significant dilution risk as 26.1M authorized shares could dilute existing holders by 64.0%. The company has minimally diluted shareholders by 5.08% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 30, 2026 |
10-Q filing | 40.8M shares outstanding |
41M | 26M |
| Mar 13, 2026 |
10-K filing | 40.5M shares outstanding |
41M | 26M |
| Nov 07, 2025 |
10-Q filing | 40.7M shares outstanding |
41M | 26M |
| May 07, 2025 |
10-Q filing | 40.3M shares outstanding |
40M | 26M |
| Mar 20, 2025 |
10-K filing | 39.3M shares outstanding |
39M | 26M |
| Nov 06, 2024 |
10-Q filing | 39.4M shares outstanding |
39M | 26M |
| Aug 08, 2024 |
10-Q filing | 39.0M shares outstanding |
39M | 26M |
| May 13, 2024 |
10-Q filing | 38.8M shares outstanding |
39M | 26M |
| Mar 20, 2024 |
10-K filing | 38.4M shares outstanding |
38M | 26M |
| Nov 09, 2023 |
10-Q filing | 38.5M shares outstanding |
39M | 26M |
| Aug 10, 2023 |
10-Q filing | 38.4M shares outstanding |
38M | 26M |
| May 12, 2023 |
10-Q filing | 38.0M shares outstanding |
38M | 26M |
| Mar 24, 2023 |
10-K filing | 37.2M shares outstanding |
37M | 26M |
| Nov 10, 2022 |
10-Q filing | 37.2M shares outstanding |
37M | 26M |
| Aug 10, 2022 |
S-3/A filing: The filing is for an offering of up to $200,000,000 in the aggregate of ordinary shares, debt securities, warrants, and units, and also includes an at the market offering of ADSs with an aggregate offering price of up to $75,000,000. |
37M | 26M |
| Aug 09, 2022 |
S-3 filing: The filing is an S-3 registration statement for a shelf offering of up to $200,000,000 in the aggregate of ordinary shares (including those represented by American Depositary Shares), debt securities, warrants, and units. |
37M | 26M |
| Aug 09, 2022 |
10-Q filing | 37.2M shares outstanding |
37M | 26M |
| Jun 22, 2022 |
S-3 filing: This prospectus relates to the proposed resale or other disposition by the selling shareholders of 2,163,694 ordinary shares, represented by American Depositary Shares (ADSs). |
37M | 10M |
| May 11, 2022 |
10-Q filing | 37.2M shares outstanding |
37M | 7.8M |
| Mar 25, 2022 |
10-K filing | 37.2M shares outstanding |
37M | 7.8M |
| Dec 14, 2021 |
8-K filing: Vaccitech acquired Avidea Technologies, Inc. for an upfront amount of $40.0 million, with $27.5 million payable in American Depositary Shares (ADSs) valued at $12.71 per ADS, plus potential milestone payments in cash and ADSs. ($27.5M proceeds) |
35M | 7.8M |
| Nov 12, 2021 |
10-Q filing | 34.8M shares outstanding |
35M | 7.8M |
| Aug 12, 2021 |
10-Q filing | 34.3M shares outstanding |
34M | 7.8M |
| Jun 14, 2021 |
10-Q filing | 34.3M shares outstanding |
34M | 7.8M |
| Apr 27, 2021 |
S-1/A filing: Vaccitech plc is offering 6,500,000 ADSs, each representing one ordinary share. The underwriters have an option for a period of 30 days from the date of this prospectus to purchase up to 975,000 additional ADSs. Up to 325,000 ADSs are reserved for sale at the initial public offering price through a directed share program. |
34M | 7.8M |
| Apr 26, 2021 |
S-1/A filing: This is an S-1/A filing for an initial public offering of American Depositary Shares representing ordinary shares of Vaccitech plc, with an option for underwriters to purchase additional ADSs and a directed share program. |
34M | 7.8M |
| Apr 09, 2021 |
S-1 filing: This is an S-1 filing for an initial public offering of American Depositary Shares (ADSs) by Vaccitech plc. Each ADS represents ordinary shares. The underwriters have an option to purchase additional ADSs, and a directed share program is available for certain related parties. |
0 | 0 |